- Home
- ZLAB vs BSM Comparison
ZLAB vs BSM Comparison
Compare ZLAB & BSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- BSM
- Stock Information
- Founded
- ZLAB 2013
- BSM 1876
- Country
- ZLAB China
- BSM United States
- Employees
- ZLAB N/A
- BSM N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- BSM Oil & Gas Production
- Sector
- ZLAB Health Care
- BSM Energy
- Exchange
- ZLAB Nasdaq
- BSM Nasdaq
- Market Cap
- ZLAB 3.0B
- BSM 3.3B
- IPO Year
- ZLAB 2017
- BSM 2015
- Fundamental
- Price
- ZLAB $26.67
- BSM $15.24
- Analyst Decision
- ZLAB Strong Buy
- BSM Buy
- Analyst Count
- ZLAB 4
- BSM 3
- Target Price
- ZLAB $52.50
- BSM $17.50
- AVG Volume (30 Days)
- ZLAB 1.1M
- BSM 417.1K
- Earning Date
- ZLAB 11-12-2024
- BSM 11-04-2024
- Dividend Yield
- ZLAB N/A
- BSM 9.78%
- EPS Growth
- ZLAB N/A
- BSM N/A
- EPS
- ZLAB N/A
- BSM 1.64
- Revenue
- ZLAB $355,748,000.00
- BSM $457,207,000.00
- Revenue This Year
- ZLAB $48.50
- BSM N/A
- Revenue Next Year
- ZLAB $47.37
- BSM $3.60
- P/E Ratio
- ZLAB N/A
- BSM $9.37
- Revenue Growth
- ZLAB 35.01
- BSM N/A
- 52 Week Low
- ZLAB $13.48
- BSM $13.94
- 52 Week High
- ZLAB $36.60
- BSM $17.80
- Technical
- Relative Strength Index (RSI)
- ZLAB 41.98
- BSM 57.92
- Support Level
- ZLAB $27.74
- BSM $14.91
- Resistance Level
- ZLAB $32.15
- BSM $15.46
- Average True Range (ATR)
- ZLAB 1.36
- BSM 0.27
- MACD
- ZLAB -0.64
- BSM 0.03
- Stochastic Oscillator
- ZLAB 3.15
- BSM 75.00
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.